Emily Drabant Conley, PhD

Dr. Conley is a biotech executive with a track record of advancing disruptive platforms in drug development. Dr. Conley is Chief Executive Officer at Renasant Bio, a biopharmaceutical company dedicated to transforming the treatment of ADPKD. Previously, Dr. Conley was CEO at Federation Bio, a clinical stage biotech where she advanced microbial cell therapies in renal disease, autoimmunity and cancer. Prior to that she spent over a decade at 23andMe, where she helped scale the company from 30 employees into the world’s leading platform for genetic-driven drug discovery. As the head of business development at 23andMe, she architected visionary partnerships across pharma and biotech.  

In addition to serving on the board of Renasant Bio, Dr. Conley serves on the boards of Nuvalent and TMRW Life Sciences and formerly served on the boards of Medrio, Lesbians Who Tech and the UCSF Alliance Health Project. 

Dr. Conley has received numerous awards and honors, including SF Business Times Most Influential Women in Business, Endpoints 20 Biopharma Leaders Under 40, Business Insider’s 30 Biotech Leaders Under 40, and Google Ventures 25 Women shaping the future of Technology. 

Prior to industry, Dr. Conley was a research fellow at the National Institutes of Health and is co-author on more than 35 academic publications. She earned her Ph.D. in Neuroscience from Stanford University and graduated summa cum laude from Vanderbilt University with a B.A.